Abstract 1948
Background
Ovarian carcinoma has the highest mortality rate among gynecologic malignancies. Primary drug resistance and multi-drug resistance are major clinical obstacles to treatment and is the main reason for the dismal 5-year survival rate of patients. Apatinib is independently developed in China as an effective small-molecule tyrosine kinase inhibitor. It mainly functions by competitively blocking the binding of VEGF with VEGFR-2 and auto-phosphorylation of VEGFR-2, thereby inhibiting the function of VEGF in stimulating endothelial cell proliferation and migration and reducing microvascular density to elicit its anti-tumor effects.
Methods
This study is a prospective, open label, single-arm clinical trial aimed to evaluate the efficacy and safety of apatinib mesylate as treatment after failure of second-line chemotherapy in patients with advanced epithelial ovarian cancer. The study enrolled 20 patients, and 17 were evaluated. Patients received an oral dosage of apatinib (500 mg or 250 mg) once daily for 28 days as an observation cycle. The efficacy of the treatment was evaluated after three treatment cycles. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were assessed.
Results
After 3 cycles of treatment, 6 (35.3%) and 2 (11.8%) patients achieved partial response (PR) and stable disease (SD), respectively. The ORR and DCR were 35.3% and 47.1%, respectively. The efficacy of apatinib was not significantly different between patients with initial dosages of 500 mg (ORR, 30%; DCR, 30%) and 250 mg (ORR, 42.8%; DCR, 71.4%). The median PFS was 2.2 months (95% confidence interval (CI), 1.0m-8.9m) and the median OS was 6.3months (95% CI, 1.5m-12.8m). The most common AEs were hypertension (70.6%), hand-foot syndrome (52.9%), and oral mucosa damage (35.3%).
Conclusions
In conclusion, oral apatinib treatment was efficacious, safe, and had no serious adverse effects in patients with advanced EOC who failed second-line chemotherapy.
Clinical trial identification
ChiCTR-OOC-16008034. Registration time: 2016-03-01.
Legal entity responsible for the study
Gynecologic Department of Traditional Chinese Medicine, Changhai Hospital.
Funding
CSCO-Hengrui Cancer Research Fund (No. Y-HR2015-244).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract